Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company dedicated to developing innovative cancer therapies. Its lead product, evorpacept, is a next-generation CD47 blocker designed to enhance immune response against tumors while minimizing hematologic toxicities. Targeting solid and hematologic malignancies, ALX is pursuing multiple clinical trials and strategic partnerships to expand treatment options. The company aims to transform cancer care through effective combination therapies and advanced immunotherapy solutions.
This description was generated via AI from an annual report. Updated about 1 year ago.